info@cymabay.com
(510) 293-8800
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
14
Nov
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update
7
Nov
CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022
4
Nov
CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting® 2022
3
Nov
CymaBay Therapeutics to Present at Upcoming Investment Conferences
1
Nov
CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development
3
Oct
CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022
14
Sep
CymaBay Therapeutics Hosting Virtual Analyst Day on September 22
6
Sep
CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
24
Aug
CymaBay Therapeutics to Participate in B. Riley’s Mini PBC Symposium on August 24, 2022
11
Aug
CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and Provides Corporate Update
1
2
3
Next >>
Show All
Scroll
